Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), today announces that the Company has contacted the US Food and Drug Administration and rescinded the October 22, 2021, letter requesting voluntary withdrawal of the NDA of Pepaxto® (INN melphalan flufenamide, also called melflufen) in the US.
January 21, 2022
· 3 min read